The SOPHiA DDM HRD Solution will enable Unipath Specialty Laboratory to retain full ownership of their data, saving time and expense
SOPHiA GENETICS, a cloud-native software company in the healthcare space and a leader in data-driven medicine, announced that Unipath Specialty Laboratory, one of the leading diagnostic brands in India, is live on the SOPHiA DDM Homologous Recombination Deficiency (HRD) Solution. Using SOPHiA GENETICS’ technology, Unipath Specialty Laboratory has launched HRD Gene Panel, its latest offering in the field of cancer genomics.
“We’re impressed by how SOPHiA GENETICS simplifies the entire process of data analysis with extreme accuracy. They not only provide the level of information and reporting that we require, but they go above and beyond to offer in-depth analysis that can better inform our clinicians and help them make data-driven decisions,” said Dr Neeraj Arora, Director, Molecular Genetics, at Unipath Specialty Laboratory. “Through the use of the SOPHiA DDM HRD Solution, Unipath Specialty Laboratory will enhance its genetic testing capabilities, improve disease research, and better serve the population in India.”
The SOPHiA DDM HRD Solution will enable Unipath Specialty Laboratory to retain full ownership of their data, saving time and expense, while offering comprehensive genomic insights powered by deep learning algorithms.
“The implementation of the SOPHiA DDM HRD Solution by Unipath Specialty Laboratory is expected to help with the incremental expansion of HRD research into India and the increase of data diversity, furthering our goal at SOPHiA GENETICS of making data-driven medicine more accessible globally,” said Ken Freedman, Chief Revenue Officer, SOPHiA GENETICS. “We look forward to seeing how this collaboration will advance cancer research and support the work of Unipath Specialty Laboratory in serving the vast community in India.”
Unipath Specialty Laboratory is spread across India with 40 labs in 11 states. Currently, Unipath Specialty Laboratory conducts more than 5 million laboratory tests annually. By leveraging the SOPHiA GENETICS DDM Platform, Unipath Specialty Laboratory will have the potential to analyse molecular data with more efficiency, saving precious time and expensive lab costs.
In addition to implementing the SOPHiA DDM HRD Solution, Unipath Specialty Laboratory will utilise SOPHiA GENETICS’ exome analysis services with both whole and clinical exome solutions, which is expected to support the identification of indication-based variants in less time with better accuracy.
